Expertise in
2
conditions

Donna L. Lancaster

Marsden, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Marsden, ENG, GB 

Overview

Donna Lancaster practices practicing medicine in Marsden, United Kingdom.

Ms. Lancaster is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Leukemia, Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Neuroblastoma.

She is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Marsden, ENG, United Kingdom
Other Locations
London, ENG, United Kingdom
Sutton Upon Derwent, ENG, United Kingdom
East Grinstead, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Enrollment Status: Recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drugs: Doxorubicin, Vincristine, Dexamethasone, Inotuzumab, Imatinib, 6-Tioguanine, Blinatumomab
Study Phase: Phase 3
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
Enrollment Status: Terminated
Publish Date: May 11, 2023
Intervention Type: Drug
Study Drugs: Selumetinib, Dexamethasone
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trial

20 Total Publications

Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.
Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.
Journal: British journal of haematology
Published: July 04, 2024

Frequently Asked Questions about Donna L. Lancaster

Is Donna L. Lancaster a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Donna L. Lancaster is classified as an Advanced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Donna L. Lancaster participate in research or clinical trials?

Yes. Donna L. Lancaster has published 20 articles and abstracts on conditions like Leukemia. You can view a list of Donna L. Lancaster's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lancaster's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile